메뉴 건너뛰기




Volumn 22, Issue SUPPL.8, 2011, Pages 5-15

Molecular approaches to personalizing management of ovarian cancer

Author keywords

Biomarkers; Early detection; Genomics; Ovarian cancer; Personalized therapy; Targeted therapy

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AUTOANTIBODY; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; GEMCITABINE; IMATINIB; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM COMPLEX; SELUMETINIB; TAXANE DERIVATIVE; TRABECTEDIN; TRASTUZUMAB; VANDETANIB; ANTINEOPLASTIC AGENT; TUMOR MARKER;

EID: 84857432805     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr516     Document Type: Conference Paper
Times cited : (75)

References (48)
  • 3
    • 63049115790 scopus 로고    scopus 로고
    • Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer InterGroup
    • Bookman M, Brady MF, McGuire WP et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer InterGroup. J Clin Oncol 2009; 27: 1419-1425.
    • (2009) J Clin Oncol , vol.27 , pp. 1419-1425
    • Bookman, M.1    Brady, M.F.2    McGuire, W.P.3
  • 4
    • 33847242677 scopus 로고    scopus 로고
    • A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer
    • Hess LM, Benham-Hutchins M, Herzog TJ et al. A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer 2007; 17: 561-570.
    • (2007) Int J Gynecol Cancer , vol.17 , pp. 561-570
    • Hess, L.M.1    Benham-Hutchins, M.2    Herzog, T.J.3
  • 5
    • 30044438368 scopus 로고    scopus 로고
    • Intraperitoneal cisplatin and paclitaxel in ovarian cancer
    • Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New Engl J Med 2006; 354: 34-43.
    • (2006) New Engl J Med , vol.354 , pp. 34-43
    • Armstrong, D.K.1    Bundy, B.2    Wenzel, L.3
  • 6
    • 77957684487 scopus 로고    scopus 로고
    • MRC OV05/EORTC 55955 investigators. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
    • Rustin GJ, van der Burg ME, Griffin CL et al. MRC OV05/EORTC 55955 investigators. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010; 376: 1155-1163.
    • (2010) Lancet , vol.376 , pp. 1155-1163
    • Rustin, G.J.1    van der Burg, M.E.2    Griffin, C.L.3
  • 7
    • 33644516543 scopus 로고    scopus 로고
    • Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range
    • Santillan A, Garg R, Zahurak ML et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol 2005; 23: 9338-9343.
    • (2005) J Clin Oncol , vol.23 , pp. 9338-9343
    • Santillan, A.1    Garg, R.2    Zahurak, M.L.3
  • 8
    • 0037404173 scopus 로고    scopus 로고
    • Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation
    • Wilder JL, Pavlik E, Straughn JM et al. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation. Gynecol Oncol 2003; 89: 233-235.
    • (2003) Gynecol Oncol , vol.89 , pp. 233-235
    • Wilder, J.L.1    Pavlik, E.2    Straughn, J.M.3
  • 9
    • 77954017982 scopus 로고    scopus 로고
    • Commentary: CA125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease
    • Bast RC Jr. Commentary: CA125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. Cancer 2010; 116: 2850-2853.
    • (2010) Cancer , vol.116 , pp. 2850-2853
    • Bast Jr., R.C.1
  • 10
    • 0037862963 scopus 로고    scopus 로고
    • Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
    • Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099-2106.
    • (2003) Lancet , vol.361 , pp. 2099-2106
    • Parmar, M.K.1    Ledermann, J.A.2    Colombo, N.3
  • 11
    • 79955447888 scopus 로고    scopus 로고
    • CA125 surveillance increases optimal respectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer
    • Fleming ND, Cass I, Walsh CS et al. CA125 surveillance increases optimal respectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol 2011; 121: 249-252.
    • (2011) Gynecol Oncol , vol.121 , pp. 249-252
    • Fleming, N.D.1    Cass, I.2    Walsh, C.S.3
  • 12
    • 78651437988 scopus 로고    scopus 로고
    • Human epidermal growth factor receptor-2-positive breast cancer: current management of early, advanced, and recurrent disease
    • Callahan R, Hurvitz S. Human epidermal growth factor receptor-2-positive breast cancer: current management of early, advanced, and recurrent disease. Current Opinion Obstet Gynecol 2011; 23: 37-43.
    • (2011) Current Opinion Obstet Gynecol , vol.23 , pp. 37-43
    • Callahan, R.1    Hurvitz, S.2
  • 13
    • 79952022701 scopus 로고    scopus 로고
    • Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors
    • Jabbour E, Cortes J, Kantarjian H. Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors. Cancer 2011; 117: 897-906.
    • (2011) Cancer , vol.117 , pp. 897-906
    • Jabbour, E.1    Cortes, J.2    Kantarjian, H.3
  • 14
    • 79952476180 scopus 로고    scopus 로고
    • Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review
    • Essaf M, Cooper K. Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review. Int J Cancer 2011; 128: 2202-2214.
    • (2011) Int J Cancer , vol.128 , pp. 2202-2214
    • Essaf, M.1    Cooper, K.2
  • 15
    • 77958102568 scopus 로고    scopus 로고
    • Personalized medicine for non-small cell lung cancer
    • Mok TS, Zhou Q, Leung L et al. Personalized medicine for non-small cell lung cancer. Expert Rev Anticancer Ther 2010; 10: 1601-1611.
    • (2010) Expert Rev Anticancer Ther , vol.10 , pp. 1601-1611
    • Mok, T.S.1    Zhou, Q.2    Leung, L.3
  • 16
    • 81155137143 scopus 로고    scopus 로고
    • Personalized medicine in a phase I trials program: the M.D. Anderson initiative
    • Abstr CRA2500
    • Tsinmberidou AM. Personalized medicine in a phase I trials program: the M.D. Anderson initiative. J Clin Oncol 2011; 29(18S): 787s (Abstr CRA2500).
    • (2011) J Clin Oncol , vol.29 , Issue.18 S
    • Tsinmberidou, A.M.1
  • 17
    • 79957811258 scopus 로고    scopus 로고
    • STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis
    • Mehra K, Mehrad M, Ning G et al. STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Front Biosci 2011; 3: 625-634.
    • (2011) Front Biosci , vol.3 , pp. 625-634
    • Mehra, K.1    Mehrad, M.2    Ning, G.3
  • 18
    • 80051549633 scopus 로고    scopus 로고
    • Ovarian cancer. In Hong WK, Bast RC Jr, Hait W, et al. (eds), Holland-Frei Cancer Medicine, 8th edition
    • Berek JS, Friedlander ML, Bast RC Jr. Ovarian cancer. In Hong WK, Bast RC Jr, Hait W, et al. (eds), Holland-Frei Cancer Medicine, 8th edition. Shelton, CT: PMPH 2010; 1344-1375.
    • (2010) Shelton, CT: PMPH , pp. 1344-1375
    • Berek, J.S.1    Friedlander, M.L.2    Bast Jr., R.C.3
  • 19
    • 0026453635 scopus 로고
    • Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation and X chromosome inactivation
    • Jacobs IJ, Kohler MF, Wiseman R et al. Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation and X chromosome inactivation. J Natl Cancer Inst 1992; 84: 1793-1798.
    • (1992) J Natl Cancer Inst , vol.84 , pp. 1793-1798
    • Jacobs, I.J.1    Kohler, M.F.2    Wiseman, R.3
  • 20
    • 18344373769 scopus 로고    scopus 로고
    • Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract
    • Cheng W, Liu J, Yoshida H et al. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med 2005; 11: 531-537.
    • (2005) Nat Med , vol.11 , pp. 531-537
    • Cheng, W.1    Liu, J.2    Yoshida, H.3
  • 21
    • 77649219639 scopus 로고    scopus 로고
    • The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory
    • Kurman RJ, Shih IEM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010; 34: 433-443.
    • (2010) Am J Surg Pathol , vol.34 , pp. 433-443
    • Kurman, R.J.1    Shih, I.E.M.2
  • 22
    • 77957354624 scopus 로고    scopus 로고
    • BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas
    • Wong KK, Tsang YT, Deavers MT et al. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol 2010; 177: 1611-1617.
    • (2010) Am J Pathol , vol.177 , pp. 1611-1617
    • Wong, K.K.1    Tsang, Y.T.2    Deavers, M.T.3
  • 23
    • 77957946398 scopus 로고    scopus 로고
    • ARID1A mutations in endometriosis-associated ovarian carcinomas
    • Wiegand KC, Shah SP, Al-Agha OM et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010; 363: 1532-1543.
    • (2010) N Engl J Med , vol.363 , pp. 1532-1543
    • Wiegand, K.C.1    Shah, S.P.2    Al-Agha, O.M.3
  • 24
    • 79952568603 scopus 로고    scopus 로고
    • Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas
    • McConechy MK, Anglesio MS, Kalloger SE et al. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol 2011; 223: 567-573.
    • (2011) J Pathol , vol.223 , pp. 567-573
    • McConechy, M.K.1    Anglesio, M.S.2    Kalloger, S.E.3
  • 25
    • 80052583874 scopus 로고    scopus 로고
    • The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma
    • King ER, Zu Z, Tsang YT et al. The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma. Gynecol Oncol 2011; 123: 13-18.
    • (2011) Gynecol Oncol , vol.123 , pp. 13-18
    • King, E.R.1    Zu, Z.2    Tsang, Y.T.3
  • 26
    • 33746646758 scopus 로고    scopus 로고
    • Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia
    • Kojima K, Konopleva M, McQueen T et al. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 2006; 108: 993-1000.
    • (2006) Blood , vol.108 , pp. 993-1000
    • Kojima, K.1    Konopleva, M.2    McQueen, T.3
  • 27
    • 79959838081 scopus 로고    scopus 로고
    • The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma
    • The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
    • (2011) Nature , vol.474 , pp. 609-615
  • 28
    • 67649440886 scopus 로고    scopus 로고
    • The biology of ovarian cancer: new opportunities for translation
    • Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nature Rev Cancer 2009; 9: 415-428.
    • (2009) Nature Rev Cancer , vol.9 , pp. 415-428
    • Bast Jr., R.C.1    Hennessy, B.2    Mills, G.B.3
  • 29
    • 52649085237 scopus 로고    scopus 로고
    • Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome
    • Tothill RW, Tinker AV, George J et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008; 14: 5198-5208.
    • (2008) Clin Cancer Res , vol.14 , pp. 5198-5208
    • Tothill, R.W.1    Tinker, A.V.2    George, J.3
  • 30
    • 77955911553 scopus 로고    scopus 로고
    • Personalizing therapy for ovarian cancer: BRCAness and beyond
    • Bast RC, Mills GB. Personalizing therapy for ovarian cancer: BRCAness and beyond. J Clin Oncol 2010; 28: 3545-3548.
    • (2010) J Clin Oncol , vol.28 , pp. 3545-3548
    • Bast, R.C.1    Mills, G.B.2
  • 31
    • 0033986363 scopus 로고    scopus 로고
    • Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study
    • Muggia FM, Braly PS, Brady MF et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2000; 18: 106-115.
    • (2000) J Clin Oncol , vol.18 , pp. 106-115
    • Muggia, F.M.1    Braly, P.S.2    Brady, M.F.3
  • 32
    • 80052245462 scopus 로고    scopus 로고
    • Modulating microtubule stability enhances the cytotoxic response of cancer cells to paclitaxel
    • Ahmed AA, Wang X, Lu Z et al. Modulating microtubule stability enhances the cytotoxic response of cancer cells to paclitaxel. Cancer Res 2011; 71: 5806-5817.
    • (2011) Cancer Res , vol.71 , pp. 5806-5817
    • Ahmed, A.A.1    Wang, X.2    Lu, Z.3
  • 33
    • 77955530763 scopus 로고    scopus 로고
    • SIK2 is a centrosome kinase required for bipolar spindle formation that provides a potential target for therapy in ovarian cancer
    • Ahmed AA, Lu Z, Jennings NB et al. SIK2 is a centrosome kinase required for bipolar spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell 2010; 18: 109-121.
    • (2010) Cancer Cell , vol.18 , pp. 109-121
    • Ahmed, A.A.1    Lu, Z.2    Jennings, N.B.3
  • 34
    • 77957336317 scopus 로고    scopus 로고
    • Tumor antigen acrosin binding protein normalizes mitotic spindle function to promote cancer cell proliferation
    • Whitehurst AW, Xie Y, Purinton SC et al. Tumor antigen acrosin binding protein normalizes mitotic spindle function to promote cancer cell proliferation. Cancer Res 2010; 70: 7652-7661.
    • (2010) Cancer Res , vol.70 , pp. 7652-7661
    • Whitehurst, A.W.1    Xie, Y.2    Purinton, S.C.3
  • 35
    • 66649118310 scopus 로고    scopus 로고
    • Therapeutic targeting of ATP7B in ovarian carcinoma
    • Mangala LS, Zuzel V, Schmandt R et al. Therapeutic targeting of ATP7B in ovarian carcinoma. Clin Cancer Res 2009; 15: 3770-3780.
    • (2009) Clin Cancer Res , vol.15 , pp. 3770-3780
    • Mangala, L.S.1    Zuzel, V.2    Schmandt, R.3
  • 36
    • 78650624101 scopus 로고    scopus 로고
    • RNA interference in the clinic: challenges and future directions
    • Pecot CV, Calin GA, Coleman RL et al. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 2011; 11: 59-67.
    • (2011) Nat Rev Cancer , vol.11 , pp. 59-67
    • Pecot, C.V.1    Calin, G.A.2    Coleman, R.L.3
  • 37
    • 77956648238 scopus 로고    scopus 로고
    • Targeted trials in ovarian cancer
    • Ledermann JA, Raja FA. Targeted trials in ovarian cancer. Gynecol Oncol 2010; 119: 151-156.
    • (2010) Gynecol Oncol , vol.119 , pp. 151-156
    • Ledermann, J.A.1    Raja, F.A.2
  • 38
    • 79953208074 scopus 로고    scopus 로고
    • Bevacizumab in the treatment of ovarian cancer
    • Eskander RN, Randall LM. Bevacizumab in the treatment of ovarian cancer. Biologics 2011; 5: 1-5.
    • (2011) Biologics , vol.5 , pp. 1-5
    • Eskander, R.N.1    Randall, L.M.2
  • 39
    • 13044283423 scopus 로고    scopus 로고
    • NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas
    • Yu Y, Xu F, Fang X et al. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci USA 1999; 96: 214-219.
    • (1999) Proc Natl Acad Sci USA , vol.96 , pp. 214-219
    • Yu, Y.1    Xu, F.2    Fang, X.3
  • 40
    • 33744528546 scopus 로고    scopus 로고
    • Biochemistry and biology of ARHI (DIRAS3), an imprinted tumor suppressor gene whose expression is lost in ovarian and breast cancers
    • Regulators and Effectors of Small GTPases. Part D. Ras Proteins
    • Yu Y, Luo R, Lu Z et al. Biochemistry and biology of ARHI (DIRAS3), an imprinted tumor suppressor gene whose expression is lost in ovarian and breast cancers. In Balch WE, Der C, Hall A (eds), Methods in Enzymology, Vol. 407: Regulators and Effectors of Small GTPases. Part D. Ras Proteins. 2006; 455-467.
    • (2006) In Balch WE, Der C, Hall A (eds), Methods in Enzymology , vol.407 , pp. 455-467
    • Yu, Y.1    Luo, R.2    Lu, Z.3
  • 41
    • 57449121645 scopus 로고    scopus 로고
    • The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells
    • Lu Z, Luo RZ, Lu Y et al. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest 2008; 118: 3917-3929.
    • (2008) J Clin Invest , vol.118 , pp. 3917-3929
    • Lu, Z.1    Luo, R.Z.2    Lu, Y.3
  • 42
    • 9144240441 scopus 로고    scopus 로고
    • Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene
    • Qu X, Yu J, Bhagat G et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 2003; 112: 1809-1820.
    • (2003) J Clin Invest , vol.112 , pp. 1809-1820
    • Qu, X.1    Yu, J.2    Bhagat, G.3
  • 43
    • 0020559574 scopus 로고
    • A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer
    • Bast RC Jr, Klug TL, St John E et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. New Engl J Med 1983; 309: 883-887.
    • (1983) New Engl J Med , vol.309 , pp. 883-887
    • Bast Jr., R.C.1    Klug, T.L.2    St John, E.3
  • 44
    • 0021842455 scopus 로고
    • Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma
    • Bast RC Jr, Siegal FP, Runowicz C et al. Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma. Gynecol Oncol 1985; 22: 115-120.
    • (1985) Gynecol Oncol , vol.22 , pp. 115-120
    • Bast Jr., R.C.1    Siegal, F.P.2    Runowicz, C.3
  • 45
    • 63149087256 scopus 로고    scopus 로고
    • Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
    • Menon U, Gentry-Maharaj A, Hallett R et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009; 10: 327-340.
    • (2009) Lancet Oncol , vol.10 , pp. 327-340
    • Menon, U.1    Gentry-Maharaj, A.2    Hallett, R.3
  • 46
    • 77954494547 scopus 로고    scopus 로고
    • A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA)
    • (Abstr 5003)
    • Lu KH, Skates S, Bevers T et al. A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA). Proc Am Soc Clin Oncol 2010: 28: (Abstr 5003).
    • (2010) Proc Am Soc Clin Oncol , vol.28
    • Lu, K.H.1    Skates, S.2    Bevers, T.3
  • 47
    • 27144489497 scopus 로고    scopus 로고
    • Potential markers that complement expression of CA 125 in epithelial ovarian cancer
    • Rosen D, Wang L, Atkinson JN et al. Potential markers that complement expression of CA 125 in epithelial ovarian cancer. Gynecol Oncol 2005; 99: 267-277.
    • (2005) Gynecol Oncol , vol.99 , pp. 267-277
    • Rosen, D.1    Wang, L.2    Atkinson, J.N.3
  • 48
    • 77952315345 scopus 로고    scopus 로고
    • Development of a multimarker assay for early detection of ovarian cancer
    • Yurkovetsky Z, Lomakin A, Skates S et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 2010; 28: 2159-2166.
    • (2010) J Clin Oncol , vol.28 , pp. 2159-2166
    • Yurkovetsky, Z.1    Lomakin, A.2    Skates, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.